Viking Therapeutics, Inc. expected to post a loss of $1.07 a share - Earnings Preview

What happened

Viking Therapeutics is expected to report no change in quarterly revenue on October 28 for the period ending September 30, 2026, with analysts expecting a loss of $1.07 per share, according to LSEG's mean estimate. The average analyst rating is buy.

Confirmed

Global impact / market context

A loss of $1.07 per share means costs are expected to exceed revenue, so investors will focus on how much cash the company spends. Since revenue is seen flat, spending control and trial progress matter more than sales growth for the stock.

Analyst inference

Analysts rate the shares buy on average, and the median 12-month price target of $97.50 sits far above the last close of $24.40. That gap suggests optimism about future results, though recent quarters mostly missed estimates, which may temper expectations.

Analyst inference

What to watch

1. Watch whether the reported loss per share matches the $1.07 estimate; past quarters mostly missed, so a wider loss would show costs running above analyst expectations. Confirmed
2. Watch for any change in the average analyst rating or the median $97.50 price target after results, since shifts there can signal revised views on the company's prospects. Proposed
3. Track spending on research and trials: with revenue expected flat, a higher loss would mean more cash used, which could raise future funding needs or slow planned work. Analyst inference

Evidence

• Original source link unavailable